What is lactosporin and why does Bacillus coagulans ATCC 7050 produce it?

Lactosporin is a ribosomally synthesized antimicrobial peptide produced by Bacillus coagulans ATCC 7050 that disrupts the cell membranes of pathogens such as Listeria monocytogenes, Salmonella spp., and Staphylococcus aureus. It functions by integrating into bacterial lipid bilayers, causing membrane permeabilization and cell death. This peptide is considered a key competitive advantage of this strain in colonization resistance within the gut environment.

Has Bacillus coagulans ATCC 7050 been tested in human clinical trials?

As of current published literature, no human randomized controlled trials have been conducted specifically on Bacillus coagulans ATCC 7050. Evidence is restricted to in vitro cell studies and animal model experiments, which limits the ability to make definitive claims about efficacy or optimal dosing in humans. Consumers should distinguish this strain from more extensively studied Bacillus coagulans strains such as GBI-30 (6086), which does have human trial data.

How does Bacillus coagulans ATCC 7050 improve gut barrier function?

In vitro studies show that Bacillus coagulans ATCC 7050 upregulates the expression of tight junction proteins occludin, claudin-1, and ZO-1 in intestinal epithelial cell lines, which are critical structural proteins that seal the paracellular space between gut cells. By increasing these protein levels, the strain reduces intestinal permeability, potentially limiting translocation of lipopolysaccharides and pathogens into systemic circulation. This mechanism has been demonstrated in cell culture models but has not yet been confirmed in human tissue.

What dose of Bacillus coagulans ATCC 7050 has been used in research?

Animal studies examining Bacillus coagulans ATCC 7050 have used doses typically ranging from approximately 10^8 to 10^9 colony-forming units (CFU) per day, administered orally. No human dosing data exists for this specific strain, making it impossible to establish a recommended effective dose for people. Commercial probiotic supplements containing Bacillus coagulans generally deliver 1–6 billion CFU per serving, though ATCC 7050 specifically is rarely the labeled strain in mainstream consumer products.

Is Bacillus coagulans ATCC 7050 safe for immunocompromised individuals?

Bacillus coagulans ATCC 7050 is a viable, spore-forming probiotic capable of germinating and transiently colonizing the gastrointestinal tract, which raises theoretical safety concerns for immunocompromised individuals, including those on chemotherapy, organ transplant recipients, or people with HIV/AIDS. No adverse events have been formally documented for this strain in such populations, but the absence of human safety data means the risk cannot be adequately characterized. Medical supervision is strongly recommended before use in any immunosuppressed or critically ill patient.

How does Bacillus coagulans ATCC 7050 survive stomach acid compared to other probiotics?

Bacillus coagulans ATCC 7050 forms spores that enable it to survive the acidic environment of the stomach, allowing delivery to the intestines where it germinates and colonizes. This spore-forming ability distinguishes it from many non-spore-forming probiotic strains that may be partially degraded by gastric acid. The spore structure provides inherent protection without requiring enteric coating technology.

What is the difference between Bacillus coagulans ATCC 7050 and other Bacillus coagulans strains?

Bacillus coagulans ATCC 7050 is a specific strain designated by its ATCC (American Type Culture Collection) accession number, which certifies its identity and purity for research purposes. Different Bacillus coagulans strains may have varying antimicrobial potency, lactosporin production levels, and colonization characteristics. The ATCC 7050 designation ensures consistency and traceability for scientific studies and quality control in commercial products.

Is Bacillus coagulans ATCC 7050 suitable for use alongside antibiotics?

Bacillus coagulans ATCC 7050 may be used during or after antibiotic therapy because its spore form can resist many antibiotics, though timing and specific antibiotic classes should be considered with healthcare providers. Unlike vegetative probiotics, this strain's ability to remain dormant as spores during antibiotic exposure and germinate afterward makes it potentially more resilient during antibiotic treatment. Individual case assessment is recommended, especially with broad-spectrum antibiotics.

Bacillus coagulans ATCC 7050

Bacillus coagulans ATCC 7050 is a spore-forming probiotic strain that produces lactosporin, an antimicrobial peptide that inhibits pathogenic bacteria including Listeria monocytogenes and Salmonella. Its primary mechanism involves modulating tight junction proteins such as occludin and claudin-1 to reinforce gut epithelial barrier integrity.

Category: Fermented/Probiotic Evidence: 2/10 Tier: Preliminary (in-vitro/animal)

Bacillus coagulans ATCC 7050 — Hermetica Encyclopedia

Origin & History

Bacillus coagulans ATCC 7050 is a gram-positive, spore-forming probiotic bacterium originally isolated from soil and environmental sources. It is cultivated through controlled fermentation and classified as a lactic acid-producing probiotic strain, with related strains like Unique IS-2 confirmed through 16S rRNA sequencing to share 45.5% G+C content.

Historical & Cultural Context

Bacillus coagulans ATCC 7050 has no documented historical or traditional medicine use in any system including Ayurveda or TCM. It is identified as a modern probiotic strain from microbiological isolation with no traditional context.

Health Benefits

• Improved intestinal health and microflora balance (demonstrated in animal studies, no human trials available)
• Enhanced gut barrier function through tight junction protein modulation (in vitro evidence only)
• Antimicrobial activity against pathogens via lactosporin peptide production (in vitro studies)
• Potential cholesterol assimilation and antioxidant effects (preliminary in vitro data)
• Reduced inflammation through cytokine modulation in intestinal cells (in vitro HT-29 cell studies)

How It Works

Bacillus coagulans ATCC 7050 produces lactosporin, a ribosomally synthesized antimicrobial peptide that disrupts pathogen cell membranes, inhibiting gram-positive and gram-negative organisms in vitro. The strain upregulates tight junction proteins occludin, claudin-1, and ZO-1 in intestinal epithelial cells, reducing paracellular permeability and supporting barrier function. Additionally, it modulates the gut microflora composition by competitively excluding pathogenic species and potentially stimulating host innate immune signaling via toll-like receptor 2 pathways.

Scientific Research

No human clinical trials, RCTs, or meta-analyses have been conducted specifically on Bacillus coagulans ATCC 7050. Evidence is limited to in vitro studies showing probiotic attributes and one controlled feeding trial in broiler chickens demonstrating improved feed conversion and intestinal morphology.

Clinical Summary

Current evidence for Bacillus coagulans ATCC 7050 is limited primarily to animal models and in vitro studies, with no published randomized controlled trials in humans specific to this strain. Animal studies have demonstrated improvements in intestinal microflora balance, reduced colonization by pathogens, and enhanced gut barrier integrity at doses equivalent to approximately 10^8 to 10^9 CFU per day. In vitro studies confirm lactosporin's antimicrobial activity but cannot establish effective human dosing or systemic bioavailability. The overall evidence base is preliminary, and extrapolating these findings to human clinical outcomes requires significant caution.

Nutritional Profile

Bacillus coagulans ATCC 7050 is a spore-forming lactic acid-producing bacterium; its nutritional contribution comes primarily from bioactive compounds rather than conventional macronutrients or micronutrients. Key bioactive compounds include: (1) Lactosporin, an antimicrobial peptide (bacteriocin-like substance) produced during fermentation, active against Listeria monocytogenes and other pathogens at concentrations reported in the range of 640–1280 AU/mL in culture studies. (2) Lactic acid (L(+) isomer), produced as the primary fermentation metabolite, contributing to gut pH modulation. (3) Short-chain fatty acids (SCFAs), including acetate and propionate, generated as secondary metabolic byproducts during colonic fermentation activity. (4) Cell wall components including peptidoglycan and lipoteichoic acids, which act as immunomodulatory ligands for Toll-like receptors (TLR-2). (5) Spore coat proteins with demonstrated surface hydrophobicity that facilitate gut epithelial adhesion. Protein content of the bacterial cell mass is approximately 40–60% dry weight (typical for Bacillus spp.), but dietary contribution at probiotic doses (typically 1×10^8 to 1×10^9 CFU per serving) is nutritionally negligible in macronutrient terms. No significant vitamin or mineral contribution is established for this specific strain at functional doses. Bioavailability note: The spore form confers superior acid and bile resistance compared to vegetative cells, with germination occurring in the small intestine upon exposure to bile salts and nutrients, improving viable cell delivery to the colon. No human pharmacokinetic data specific to ATCC 7050 is currently available.

Preparation & Dosage

No clinically studied human dosage ranges are available for ATCC 7050. Related strains maintain viability at 10^9 CFU/g in probiotic foods, though no standardization exists for this specific strain. Animal studies used unspecified concentrations in feed supplementation. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

Other probiotic strains, prebiotic fibers, digestive enzymes, L-glutamine, zinc carnosine

Safety & Interactions

Bacillus coagulans strains generally are considered safe for healthy adults, and ATCC 7050 has not been associated with serious adverse events in the animal or in vitro studies conducted to date. Because it is a spore-forming organism capable of transient gut colonization, immunocompromised individuals, critically ill patients, or those with short bowel syndrome should avoid use without medical supervision. No specific drug interactions have been documented for ATCC 7050, though concurrent use with broad-spectrum antibiotics would likely reduce its viability and efficacy. Safety data during pregnancy and lactation is absent for this specific strain, and use should be avoided until human safety studies are available.